2CUREX AB SEK-10 (F:2QE) — Market Cap & Net Worth
Market Cap & Net Worth: 2CUREX AB SEK-10 (2QE)
2CUREX AB SEK-10 (F:2QE) has a market capitalization of $3.63 Million (€3.10 Million) as of June 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #29164 globally and #2530 in its home market, demonstrating a -6.27% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying 2CUREX AB SEK-10's stock price €0.15 by its total outstanding shares 25102916 (25.10 Million). Review 2CUREX AB SEK-10 (2QE) financial obligations to assess the company's total debt and financial obligations.
2CUREX AB SEK-10 Market Cap History: 2019 to 2026
2CUREX AB SEK-10's market capitalization history from 2019 to 2026. Data shows change from $37.71 Million to $4.30 Million (-23.29% CAGR).
2CUREX AB SEK-10 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how 2CUREX AB SEK-10's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
228.59x
2CUREX AB SEK-10's market cap is 228.59 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $20.57 Million | $90.00K | -$29.77 Million | 228.59x | N/A |
Competitor Companies of 2QE by Market Capitalization
Companies near 2CUREX AB SEK-10 in the global market cap rankings as of June 19, 2026.
Key companies related to 2CUREX AB SEK-10 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
2CUREX AB SEK-10 Historical Marketcap From 2019 to 2026
Between 2019 and today, 2CUREX AB SEK-10's market cap moved from $37.71 Million to $ 4.30 Million, with a yearly change of -23.29%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €4.30 Million | +133.12% |
| 2025 | €1.84 Million | +132.59% |
| 2024 | €792.39K | -84.79% |
| 2023 | €5.21 Million | -74.68% |
| 2022 | €20.57 Million | -53.33% |
| 2021 | €44.08 Million | -9.52% |
| 2020 | €48.72 Million | +29.18% |
| 2019 | €37.71 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of 2CUREX AB SEK-10 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.63 Million USD |
| MoneyControl | $3.63 Million USD |
| MarketWatch | $3.63 Million USD |
| marketcap.company | $3.63 Million USD |
| Reuters | $3.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About 2CUREX AB SEK-10
2cureX AB (publ) operates as a medical technology company in Europe. The company's principal product is IndiTreat, an IVD test for the treatment of cancer by establishing 3D copies of the patient's tumor and directly testing them against therapies. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.